Understand what your liver function testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Alcoholic liver disease and the hepatic markers behind it
Alcoholic liver disease biomarkers are blood signals that reveal how alcohol stresses, injures, and reshapes the liver. They capture three main stories: cell damage, bile handling, and the liver’s ability to make vital proteins. Enzymes that normally live inside liver cells spill into blood when membranes are disrupted (aspartate aminotransferase, AST; alanine aminotransferase, ALT), and from bile duct cells when bile flow is disturbed (gamma‑glutamyl transferase, GGT). Pigment processing can falter, allowing breakdown products of red blood cells to build up (bilirubin). The liver’s “factory output” is reflected by blood proteins it makes, especially the main carrier protein (albumin) and clotting factors (prothrombin and related coagulation proteins). Blood cell patterns can echo alcohol’s effects on marrow and the liver (mean corpuscular volume, MCV; platelet count). Some markers point to alcohol exposure itself rather than liver damage (carbohydrate‑deficient transferrin, CDT; phosphatidylethanol, PEth). Together, these biomarkers translate alcohol’s impact into measurable changes, helping clinicians see the extent and nature of liver involvement and track biological recovery when drinking behavior changes.
Why a liver panel matters when alcohol is in the picture
Alcoholic liver disease blood tests track how well the liver is processing, detoxifying, and building proteins—functions that ripple across metabolism, hormones, brain chemistry, fluid balance, and immunity. They reveal early injury from alcohol exposure, distinguish active inflammation from scarring, and flag complications that affect the whole body. Typical reference ranges: AST about 10–40, ALT 7–40, GGT 10–60, bilirubin 0.3–1.2, albumin 3.5–5.0. For enzymes (AST, ALT, GGT), optimal sits toward the low-normal range, reflecting minimal cell injury; for albumin, mid-to-high normal reflects robust liver synthesis; bilirubin is best low-normal. In alcohol-related injury, AST often exceeds ALT (frequently a ratio above 2), GGT rises with alcohol induction, bilirubin climbs when excretion is impaired (jaundice, dark urine, itching), and albumin falls in chronic disease (edema, ascites, fatigue). Men tend to have slightly higher GGT and ALT than women; in pregnancy, albumin and bilirubin run lower from hemodilution. Very low AST, ALT, or GGT usually means little active damage, but in advanced cirrhosis they can appear deceptively normal because few hepatocytes remain to leak enzymes. Low bilirubin is typically benign. Low albumin is different—it signals reduced hepatic protein synthesis, worsening portal hypertension, and susceptibility to infections; in children it can impair growth. Big picture: these markers integrate liver cell integrity (AST/ALT), alcohol effect and bile flow (GGT, bilirubin), and synthetic reserve (albumin). Patterns help anticipate bleeding risk, encephalopathy, sarcopenia, bone loss, and cardiovascular and endocrine effects, guiding evaluation of long-term outcomes in Alcoholic Liver Disease.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
The reach of a liver panel in alcohol-related disease
Alcoholic liver disease (ALD) blood testing provides a window into the health of your liver, a central organ for energy production, metabolism, detoxification, and immune regulation. When the liver is damaged by alcohol, its ability to support these vital systems is compromised, affecting everything from cardiovascular health to cognition. At Superpower, we assess ALD risk and liver function by measuring five key biomarkers: AST, ALT, GGT, bilirubin, and albumin. AST (aspartate aminotransferase) and ALT (alanine aminotransferase) are enzymes found in liver cells. When liver cells are injured by alcohol, these enzymes leak into the bloodstream, signaling cellular stress or damage. GGT (gamma-glutamyl transferase) is another enzyme that rises with alcohol exposure and bile duct stress, making it especially sensitive to alcohol-related injury. Bilirubin is a yellow pigment produced when red blood cells break down; elevated levels can indicate impaired liver processing or bile flow. Albumin is the main protein made by the liver, reflecting its ability to synthesize essential proteins for fluid balance and transport. Healthy levels of these biomarkers suggest stable liver cell integrity, efficient detoxification, and robust protein synthesis. In ALD, elevations in AST, ALT, GGT, or bilirubin, or a drop in albumin, point to disrupted liver function, which can undermine metabolic stability and systemic health. Interpretation of these results depends on factors like age, sex, pregnancy, acute illness, medications, and even lab methods. These variables can influence biomarker levels, so results are always considered in clinical context.
Frequently Asked Questions
References
- European Association for the Study of the Liver. (2018). EASL clinical practice guidelines: Management of alcohol-related liver disease. *Journal of Hepatology*, *69*(1), 154-181. https://doi.org/10.1016/j.jhep.2018.03.018
- Hosseini N, Shor J, Szabo G (2019). Alcoholic hepatitis: A review. *Alcohol and Alcoholism*, *54*(4), 408-416. https://doi.org/10.1093/alcalc/agz036
- Majhi S, Baral N, Lamsal M, Mehta KD (2006). De Ritis ratio as diagnostic marker of alcoholic liver disease. *Nepal Medical College Journal*, *8*(1), 40-42. https://pubmed.ncbi.nlm.nih.gov/16827089/
- Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R (2013). Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. *Hepatology*, *58*(5), 1836-1846. https://doi.org/10.1002/hep.26338
- Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A (2014). Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. *Alcoholism: Clinical and Experimental Research*, *38*(6), 1706-1711. https://doi.org/10.1111/acer.12442
